Skip to main content

Xarelto Makers’ Hopes Squashed A Second Time

Xarelto Makers’ Hopes Squashed A Second Time

Xarelto Makers’ Hopes Squashed A Second Time

Introduction

Portola Pharmaceuticals received news of a second-time delay from the U.S. Food & Drug Administration (FDA) regarding the approval of AndexXa, an antidote developed to monitor uncontrollable bleeding linked to Xarelto and Eliquis. The delay is caused due to some additional data required by the FDA, shifting the expected approval date from February 3, 2018, to May 4, 2018.

Prior to this, the FDA had delayed the August of 2016 approval, when it reverted requesting more information about Portola’s manufacturing and additional data for inclusion of two other anticoagulants in the label: edoxaban and enoxaparin. The makers of anticoagulants Xarelto and Eliquis, Bayer and Johnson & Johnson as well as Pfizer and Bristol-Myers Squibb, have been funding Portola to develop the antidote in view that it will bring the much awaited legal respite be ‘the legal sheath’ to help them evade new lawsuits tied to the bleeding risks of their drugs.

Previously three verdicts have been announced in favor of the defendants by Honorable Eldon E. Fallon presiding MDL – 2592: Xarelto Products Liability Litigation in the U.S. District Court for the Eastern District of Louisiana.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!